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Abstract
Background:  Endometrial polyps (EMPs) are commonly encountered in routine surgical
pathology practice, but opinions differ on whether they are intrinsically a marker for concurrent
or subsequent malignancy. The objectives of the present study are 1) to investigate the age-group
in which EMP are most commonly encountered 2) to document the age-group in which EMP are
most commonly associated with malignancies 3) To investigate whether the age of diagnosis of the
various carcinoma subtypes in EMPs is congruent with published data on similar malignancies arising
in non-polypoid endometrium and 4) To investigate whether the histologic subtype distribution of
malignancies associated with EMPs are similar or different from the distribution of malignancies
arising from non-polypoid endometrium based on published data.
Patients and methods: All cases of EMPs were retrieved from the files of Yale-New Haven
Hospital for the period 1986–1995. The patients were divided into 5 age groups: Each group was
further subclassified based on an association (or lack thereof) of EMPs with endometrial carcinoma.
Chi-square test was used to compare the proportion of malignancy associated EMPs between the
age groups.
Results: We identified 513 EMPs, of which 209 (41%) were from biopsy specimens and 304 (59%)
from hysterectomy specimens. Sixty six (13%) of all EMPs were malignant. The 66 malignant EMPs
included 58 endometrioid, 6 serous, 1 carcinosarcoma, and 1 clear cell carcinoma. In age group
>35, only 1(2.5%) of 40 EMPs was associated with endometrial malignancy. In contrast, 37(32%) of
115 EMPs were associated with malignancy in the age group > 65. The frequency of malignant EMPs
increased with age and reached statistical significance in the age group >65 (p < 0.001). The most
common histologic type of malignancy was endometrioid adenocarcinoma.
Conclusions: EMPs show statistically significant age dependent association with malignant tumor
involvement. Careful search for malignancy, particularly in women with multiple risk factors is
advised in daily practice. Additional studies are needed to address the histological features and
immunohistochemical profiles in the context of association between endometrioid and high-grade
endometrial carcinoma and endometrial polyps.
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Background
Endometrial polyps (EMPs) are generally considered
benign proliferative lesions and are commonly encoun-
tered in routine surgical pathology practice. The usual his-
tological pattern of endometrial polyps is characterized by
irregular proliferative glands, with a fibrotic stroma con-
taining thick-walled blood vessels [1]. The morphologic
diversity of endometrial polyps is reflective of the mor-
phologic spectrum of the background endometrium from
which EMPs arise. As such, EMPs may range from atrophic
to hyperplastic to carcinomatous. However, opinions dif-
fer on whether EMPs are intrinsically a marker for concur-
rent or subsequent malignancy. Endometrial polyps were
identified in 12–34% of uteri containing endometrial car-
cinoma in two earlier studies [2,3]. In another case-con-
trol study examining previous pathology in women
diagnosed with endometrial carcinoma, endometrial pol-
yps were twice as likely to be detected than in the control
group [4]. Rarely, serous endometrial intraepithelial carci-
noma (EIC), the presumptive early form of uterine papil-
lary serous carcinomas, may be identified as very minute
foci in EMPs [5,6]. This finding may be interpreted as the
EMP homologue of similar changes that are occasionally
identified in non-polypoid atrophic endometrium. How-
ever, given that nonrandom chromosomal aberrations
and monoclonality that have been demonstrated in EMPs
[7,8], an alternate interpretation is that molecular and/or
cytogenetic alterations inherent to EMPs facilitate a neo-
plastic transformation. The latter interpretation would
imply that endometrial polyps are a risk factor for the
development of endometrial tumors. And indeed a possi-
ble association between endometrial polyps and endome-
trial malignancy in postmenopausal women has been
suggested couple of decades ago [4]. However, there is no
direct evidence for a greater propensity of polypoid
endometrium to undergo malignant change as compared
to the adjacent normal endometrium, and EMP may sim-
ply represent am embodiment of the greater propensity of
the host endometrium to develop proliferative/neoplastic
changes in general [9]. A recent study designed and con-
ducted to investigate the pathological significance of
EMPs and their association with pre-malignant and malig-
nant conditions failed to supply evidence of such associa-
tion. That study involved a large cohort of patients seen in
outpatient hysteroscopy clinic for abnormal uterine
bleeding. To determine the magnitude of malignant
potential among polyps, the authors compared the path-
ological findings in polyps with non-polypoid specimens.
The comparative analysis established that endometrial
hyperplasia was more frequent in endometrial specimens
with polyps, but the incidence of frank carcinoma in poly-
poid and non-polypoid endometrium remained the
same. Although not age stratified, the study showed that
in abnormal uterine bleeding, hyperplasia presented
more frequently in women with EMPs compared to those
without polyps, but cancer involvement regardless of the
histological pattern was not significantly different [9].
Similar results and failure to establish any association of
endometrial polyps and carcinoma were demonstrated in
another recent study dealing with endometrial polyp
characteristics in menopausal women on hormonal
replacement therapy [10].
Most standard pathology texts list endometrial polyps as
being most prevalent in perimenopausal women and sug-
gest possible association between polyps and malignant
involvement [9,11]. However, there has been no detailed
age-based analysis of the incidence and malignant
involvement of EMPs. In this report, age-related differ-
ences in the incidence of EMP at the time of diagnosis in
the practice of a busy academic center is examined, with a
detailed analysis of the incidence and histologic subtypes
of malignancies associated with EMPs. The objectives of
the study are 1) to investigate the age-group in which EMP
are most commonly encountered in routine surgical
pathology practice 2) to document the age-group in which
EMPs are most commonly associated with malignancies
3) To investigate whether the age of incidence of the vari-
ous carcinoma subtypes in EMPs at the time of diagnosis
is congruent with published data on similar malignancies
arising in non-polypoid endometrim and 4) To investi-
gate whether the histologic subtype distribution of malig-
nancies associated with EMPs is similar or significantly
different from the distribution of malignancies arising
from non-polypoid endometrium.
Patients and methods
Case retrieval and pathologic classifications
All cases with a diagnosis of EMP were retrieved from the
computerized database of the Pathology Department at
Yale-New Haven Hospital for the 10-year-period from
1986 to1995. All cases were further investigated for
involvement of endometrial cancers including malignan-
cies without myometrial invasion; histologic subtypes of
all malignant tumors were catalogued. Histologic types of
endometrial malignancies were characterized according to
the WHO classification [12]. All cases were reviewed
microscopically and confirmed by a second pathologist.
For endometrial cancer with mixed histologic type, the
presence of a second component was considered if it
involved more than 10% of all available sections contain-
ing tumor. The cases of endometrial malignancy involving
both EMPs and non-polyp endometrium, were classified
into the category of EMPs with cancer involvement.
Patients groups
For comparative purposes, the patients were divided into
5 age groups: 25–35; 36–45; 46–55; 56–65; and >65
years; and each group was further classified based on an
association (or lack thereof) with endometrial carcinoma.World Journal of Surgical Oncology 2005, 3:8 http://www.wjso.com/content/3/1/8
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A starting point of 25 years of age was selected due to the
very low incidence of endometrial polyps in patients
below this age. Two patients (ages 18 and 19) were
excluded from the study as they did not represent a suffi-
ciently large for statistical analysis group. The proportion
of both groups (polyps associated with malignancies
(malignant polyps) and polyps not associated with malig-
nancies (benign polyps) were statistically compared for
each of the aforementioned age-groups. Subsequently, we
merged the younger age groups and preserved the >65
year group, which we referred to as "postmenopausal",
since significant differences were observed in this specific
subset of patients. Larger age groups were arbitrarily des-
ignated as reproductive years (25–45), perimenopause
(shortly before or after menopause, 46–65) and postmen-
opause (>65) and statistically analyzed. The postmeno-
pausal status of all women above the age of 65 was
verified and the term "postmenopausal" was occasionally
used when referring to this particular age group. Our use
of this term, although arbitrary, was important in order to
put the emphasis on the fact that any pathomorphological
findings in this age group are unlikely to be attributed to
changes characteristic of the cycling endometrium.
Statistical analysis
Chi-square test was used to compare the proportion of
malignancy associated EMPs between the age groups and
in regards to particular histological type of malignancies.
Results
Out of all diagnostic and therapeutic procedures per-
formed over this period, a total of 513 EMP were identi-
fied. The latter included 304 (59%) endometrial biopsies/
curetting samples, and 209 (41%) hysterectomy speci-
mens. In cases in which endometrial biopsies and hyster-
ectomies both showed presence of EMP, only the
hysterectomy specimen was considered. The age of
patients ranged from 18–91 years with a median of 54
years. Sixty-six (13%) of 513 EMPs were malignant. The
histological subtype distribution of those 66 malignancies
included 58 endometrioid (87%), 6 serous (9%), 1 carci-
nosarcoma, and 1 clear cell carcinoma. No mixed histo-
logical type of endometrial cancer was found in our series.
The incidence of EMP peaked at age group 46–55 years,
which was similar to previous reports. In age group 25–
Frequency of occurrence of benign endometrial polyps by  age group Figure 1
Frequency of occurrence of benign endometrial pol-
yps by age group. The frequency of occurrence of EMPs at 
the time of diagnosis peaked in the age group 46–55 years 
(29%), followed by 36–45 (27%), 56–65 (18%) and >65 years 
(17%). The incidence of EMPs in the age group 25–35 years 
was significantly lower (9%).
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Frequency of occurrence of malignant endometrial polyps by  age group Figure 2
Frequency of occurrence of malignant endometrial 
polyps by age group. In age group 25–35 years, only 2.5% 
of the EMPs were associated with endometrial malignancy. In 
contrast, in the age group >65 years, 32% of the EMPs were 
associated with malignancy.
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35, only 1 (2.5%) of 40 EMPs was associated with
endometrial malignancy. In contrast, 37 (32%) of 115
EMPs were associated with malignancy in the age group
>65 years (Figure 1; Figure 2). The frequency of EMPs with
malignancy involvement increased with age and reached
statistical significance (p < 0.001) in the age group >65
years (Figure 3). The most common histological type of
malignancy was endometrioid carcinoma, followed by
serous carcinoma. The same statistically significant differ-
ence for age group >65 years (p < 0.05) remained when
larger age groups, including reproductive (25–45), peri-
menopausal (46–65) and postmenopausal (>65) patients
were compared (Figure 4).
Discussion
Our results indicated a strong age dependent association
of endometrial polyps and endometrial carcinoma. A lin-
ear relationship in the association rate of EMPs with
malignancies and increasing age was observed, with the
highest association rate identified in the >65 years age
group, where 32% of the EMPs were associated with
malignancy. Histological evaluation and characterization
of the morphological types of carcinoma demonstrated
that the vast majority (87%) of endometrial carcinomas
associated with EMPs were of endometrioid, followed by
the serous type (9%). These relative proportions of both
major histological subtypes are in accordance with the
well-known distribution of similar subtypes of endome-
trial carcinoma in non-polypoid endometrium [12] and
thus demonstrates that neither histologic subtype is more
likely than the other to develop in a polyp as compared to
the adjacent endometrium. The majority of the serous
carcinomas developed in the oldest age group (>65 years),
whereas the majority of the endometrioid carcinomas
occurred in the 46–55 age group, followed by the 36–45
age group. These age distributions are in accordance with
the general concept of Type I and Type II endometrial car-
cinogenesis [13] and provide some evidence suggesting
that carcinomas developing in EMPs do not necessarily
have clinicopathologic differences from carcinoma arising
in the background endometrium. It is well established
that serous carcinoma may exist as a minute foci in the
endometrium devoid of myometrial invasion and still
show extrauterine involvement [14-16]. In a study of
EMPs with serous carcinoma involvement with no or min-
imal invasion, Silva et al., [17] reached similar findings: in
6 (37.5%) of 16 cases in that study, there was evidence of
extra uterine involvement at presentation. The similarities
between the patients who presented with advanced dis-
ease and the patients who presented with initial stage dis-
ease, suggested that serous carcinoma involving
endometrial polyps may represent one aspect of a multi-
centric disease in which, the entire female genital tract and
the abdominal peritoneal surfaces would be at high risk
for concurrent or subsequent involvement by serous carci-
noma even in the absence of myometrial invasion [17] or
Distribution of benign and malignant endometrial polyps by  age group Figure 3
Distribution of benign and malignant endometrial polyps by 
age group Although the incidence of EMPs at the time of 
diagnosis in the age group > 65 years was among the lowest, 
the incidence of malignancy associated EMPs was the highest.
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Benign and malignant endometrial polyps by age group Figure 4
Benign and malignant endometrial polyps by age group
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the extrauterine disease may represent transtubal metasta-
sis [18,19].
This study also confirms previous findings that EMPs are
most prevalent in the perimenopausal age group. The rea-
son(s) for this age-segregation, which has remained
remarkably consistent across various studies since the
mid-fifties, is unclear. Chavez et al., [20] speculated that
with the introduction of new minimally invasive
technologies (such as office hysteroscopy and sonohyster-
ograms), the demographics of patients with EMPs will
change over time as younger women undergoing evalua-
tion for infertility will have "latent" EMPs discovered.
However, when the authors compared the mean ages of
women with EMPs in 1990 and 1996, there was no statis-
tically significant difference. In addition, multiple EMPs
are more prevalent in the postmenopausal women (26%)
as compared with their premenopausal (15%) counter-
parts with EMPs. These findings suggest that the factor, or
the constellation of factors responsible for the above men-
tioned observation is intrinsic to the endometrial polyps
and surrounding endometrium condition depending on
the age group. Lower incidence of endometrial polyps in
the younger age group may be attributed to a possible
spontaneous regression mechanism, which is characteris-
tic of the cycling endometrium in young reproductive age
women.
Despite the supportive evidence of no difference in the
clinico-pathological features and overall distribution of
carcinomas arising from EMPs with those arising from
non-polypoid endometrium, our data suggest a strong age
dependent association between the presence of EMPs and
involvement by endometrial carcinoma. The pathogenesis
and mechanisms underlying such association are complex
and not well established. Recently published data,
however, provided some clue of significant differences in
receptor expression, response to stimuli, and apoptosis
regulation in EMPs compared to benign non-polypoid
endometrium which could potentially elucidate some
aspects of the possible malignant potential of EMPs.
Estrogen and progesterone act as modulators of endome-
trial proliferation and differentiation through their recep-
tors. Glandular epithelial expression of estrogen and
progesterone receptors in polyps is not significantly
different from that of the normal cycling endometrium.
However, fewer stromal cells express estrogen and proges-
terone receptors in polyps which suggests that EMPs may
result from a decrease in estrogen and progesterone recep-
tors in the stromal cells [21]. In addition, although EMPs
depend partially on estrogen receptors and grow in
response to estrogen stimulation, their growth is not
entirely dependent on them, this is especially so in post-
menopausal women. The presence of c-erbB2 over-expres-
sion in endometrial polyps, in association with higher
proliferation rates were established in a recent study [22].
This finding could explain the presence of polyps showing
signs of proliferation even when the adjacent
endometrium is atrophic. Thus, C-erbB2 over-expression
in endometrial polyps and not in the adjacent atrophic
mucosa may render polyps more sensitive to the combi-
nation of high gonadotropins and low estrogen levels,
which is characteristic in the postmenopausal women.
Another significant histological finding is the glandular
epithelia hyperplasia in C-erbB2 -positive polyps as
opposed to rather atrophic architecture in C-erbB2 -nega-
tive polyps [22]. These findings indicate that the
relationship between the expression of estrogen receptors
and cell proliferation in normal endometrium and EMPs
differ significantly. The balance between mitotic activity
and apoptosis, which regulates normal endometrial
development in EMPs also shows significant alterations.
Bcl-2 is a proto-oncogene, which prolongs the cell survival
by inhibiting apoptosis. Bcl-2 expression has been
characterized in normal cycling endometrium. Recent
studies have also observed that Bcl-2 is strongly expressed
in hyperplastic and malignant endometrium [23]. A local-
ized increase in Bcl-2 expression and consequential
decline or cessation of apoptosis may be another mecha-
nism underlying the pathogenesis of endometrial polyps
[24]. Elevated Bcl-2 expression results in failure of the
polyp tissue to undergo normal cycle dependent sequence
of proliferation, differentiation and shedding. These data
imply that the relationship between receptor expression,
cell proliferation and apoptosis in normal and polypoid
endometrium differ significantly. Such differences com-
bined with the nonrandom chromosomal aberrations
and monoclonality, suggest that EMPs may provide a suit-
able microenvironment for the development of malig-
nancy, particularly epithelial cancers. In this aspect, the
molecular and/or cytogenetic alterations inherent to
EMPs in a postmenopausal background could be viewed
as factors facilitating and contributing to the process of
malignant transformation. Our results showed a strong
association of EMPs in postmenopausal patients with
endometrial cancer. It raised the possibility that EMPs in
postmenopausal women could represent some intermedi-
ate stage in the development of carcinoma. A similar sug-
gestion was proposed in a study evaluating the spectrum
of pathological findings in Tamoxifen treated breast can-
cer patients whom develop polyps and carcinoma signifi-
cantly more frequently than the general population [25].
Also in favor of this hypothesis were the results provided
by Silva et al., who found that 10 (76%) of 13 Tamoxifen-
related endometrial carcinomas were associated with
EMPs [26].
One potential limitation of our study is our lack of con-
sideration of the impact of variables such as hypertension,World Journal of Surgical Oncology 2005, 3:8 http://www.wjso.com/content/3/1/8
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obesity and family history. However, since data regarding
such possible confounders were not available to us, we set
the goals of our investigation to be primarily focused on
age related distribution of coinciding morphologic
findings. Although we are aware of the limitations of our
study and the introduced analytical bias, drawbacks that
certainly pertain to any similar retrospective
pathomorphologic study, we feel that we have adequately
addressed the proposed investigative tasks according to
the initially set scope of the study. By using the database
of Yale-New Haven Hospital, we collected and analyzed a
significant number of cases over an extensive period of
time and thereby our study population constituted an
adequate representation of the general population in
respect to the morphological parameters we investigated.
In summary, the age distribution, histological subtype
distribution, and peak incidence of EMPs was similar to
previous reports. In contrast, EMPs in postmenopausal
women showed a significantly higher association with
malignant tumor involvement. Careful microscopic
search for malignancy in patients with multiple risk
factors, particularly in postmenopausal women is advised
in daily surgical pathology practice.
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